Effects by botulinum toxin in patients with jaw muscle pai
- Conditions
- Myogenous temporomandibular disorders (TMDM)Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Registration Number
- CTIS2024-514739-12-00
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
A diagnosis of myalgia or myofascial pain with referral according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) axix I, Female aged 20 – 45 years, A characteristic pain intensity of > 40/100, Pain upon digital palpation of at least one of the masseter muscles
Difficulties understanding the Swedish language, Known allergy to botulinum toxin or antibiotics, Use of muscle relaxants, antidepressant, neuropsychiatric, or anticoagulant drugs, Use of analgesic or anti-inflammatory medication during the 48 hours preceding biopsy, Previous treatment with BTX during the last 12 months, Infection at the injection site, Systemic inflammatory connective tissue diseases (e.g. rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) c) widespread pain (e.g. fibromyalgia), Widespread pain (e.g. fibromyalgia), Neuromuscular disorders (e.g. craniomandibular dystonia, myasthenia gravis), Diagnosed or severe psychiatric disease (e.g. schizophrenia, bipolar disorder), Neuropathic pain, Pain of dental origin, History of trauma to the face, head or neck (incl. orthognathic surgery), Pregnancy or nursing
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method